Maxcyte (MXCT) Common Equity (2020 - 2025)
Historic Common Equity for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $180.3 million.
- Maxcyte's Common Equity fell 1548.37% to $180.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $180.3 million, marking a year-over-year decrease of 1548.37%. This contributed to the annual value of $206.3 million for FY2024, which is 1116.27% down from last year.
- As of Q3 2025, Maxcyte's Common Equity stood at $180.3 million, which was down 1548.37% from $190.7 million recorded in Q2 2025.
- Maxcyte's 5-year Common Equity high stood at $264.1 million for Q3 2021, and its period low was $78.8 million during Q2 2021.
- For the 5-year period, Maxcyte's Common Equity averaged around $223.6 million, with its median value being $232.8 million (2023).
- Per our database at Business Quant, Maxcyte's Common Equity surged by 69125.34% in 2021 and then crashed by 1548.37% in 2025.
- Over the past 5 years, Maxcyte's Common Equity (Quarter) stood at $262.9 million in 2021, then fell by 3.4% to $254.0 million in 2022, then fell by 8.58% to $232.2 million in 2023, then decreased by 11.16% to $206.3 million in 2024, then decreased by 12.59% to $180.3 million in 2025.
- Its last three reported values are $180.3 million in Q3 2025, $190.7 million for Q2 2025, and $199.4 million during Q1 2025.